AzTrials
AzTrials

Post Partum WomenVISIMATNCT07653646

Restrictions on Maternity Ward Visits: Current Situation, Challenges and Recommendations in the Auvergne Rhone-Alpes Region (AuRA)

A study testing psychological assessment in people with Post Partum Women and Newborn Health, run by Centre Hospitalier Annecy Genevois at 2 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Maternal mental health in the postpartum period is a major public health issue in France. The 2021 National Perinatal Survey highlights high prevalence rates of mental health disorders among mothers, with 27.6% experiencing anxiety disorders, 16.7% experiencing depressive disorders and 5.4% having suicidal thoughts. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Post Partum Women, Newborn Health
What is being tested?
psychological assessment
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8,000 participants
Where
2 sitesFrance
Study dates
19 Jun 2026to Jun 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult female patient (aged 18 or over),
  • Female patient admitted to the maternity ward with her newborn baby or babies,
  • Length of stay in the maternity ward of 48 hours or more,
  • Female patient who has been informed about the study and has given her free, informed verbal consent to participate in the study.

Who cannot join

  • Patients who have already participated in this study,
  • Patients whose newborn(s) are hospitalised in neonatal units, neonatal intensive care units or neonatal resuscitation units,
  • Patients who have given birth to three or more newborns (triplets or more),
  • Patient whose newborn(s) has/have died,
  • Patient unable to understand spoken or written French, making self-assessment impossible,
  • Patient under guardianship, curatorship or placed under judicial protection,
  • Patient not covered by the French social security system.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

France2 sites, 2 recruiting
  • Centre Hospitalier Annecy Genevois

    Annecy, 74370

    Noellie FANTINATO

    Recruiting
  • CH Annecy Genevois

    Épagny, Auvergne-Rhône-Alpes, 74370

    Marion Beucher, PhD, +33450637032 ext. +33, mbeucher@ch-annecygenevois.fr

    Not yet recruiting

Other trials in France

About this study

Official title: Restrictions on Maternity Ward Visits: Current Situation, Challenges and Recommendations in the AuRA Region

Maternal mental health in the postpartum period is a major public health issue in France. The 2021 National Perinatal Survey highlights high prevalence rates of mental health disorders among mothers, with 27.6% experiencing anxiety disorders, 16.7% experiencing depressive disorders and 5.4% having suicidal thoughts. Between 2016 and 2018, suicide was also the leading cause of maternal mortality in the year following childbirth, underscoring the severity and frequency of these disorders. In response, international guidelines, notably those of the World health Organisation (WHO), as well as national policies such as the 'First 1,000 Days' strategy, emphasise the importance of early, enhanced and individualised postnatal support. In France, this postpartum care tends to be structured around the Early Postnatal Interview and the recommended use of validated screening tools such as the Edinburgh Postnatal Depression Scale (EPDS).

However, the quality of postpartum care depends not only on screening and clinical follow-up, but also on organisational and environmental factors. Among these, the arrangements for maternity ward visits constitute a potential determinant of patients' experiences, likely to influence both their mental state, their rest, the establishment of breastfeeding and, indirectly, the health of the newborn. The exceptional measures implemented during the Covid-19 pandemic, notably the restriction of visits, have shown generally favourable effects, with improved satisfaction among patients and healthcare staff, better conditions for rest, facilitation of breastfeeding and a perceived improvement in working conditions.

Read more

However, these data were collected in an exceptional health context, which may introduce biases linked to the social, emotional and organisational constraints specific to this period. Their extrapolation to routine practice therefore remains uncertain. Furthermore, in the absence of specific national guidelines governing maternity ward visits, the current regulatory framework remains unclear and practices vary between institutions, often relying on local decisions that have not been scientifically evaluated.

Against this backdrop, the VISIMAT study aims to characterise maternity ward visiting arrangements outside of any exceptional circumstances and to assess their impact on the health of mothers and newborns, as well as on healthcare workers' working conditions. Its aim is to provide a scientific basis to inform the development of standardised recommendations and prevention messages.

Being tested
psychological assessment
Keywords
maternity wards visiting, mother health, newborn health

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • psychological assessmentOther

    The only intervention resulting from the research consists of referring patients with an EPDS score ≥ 10 and/or a positive response to item 10 of this scale ('has already thought about harming themselves') to a psychologist.

Study groups in NCT07653646
Study groupRoleWhat they receive
Intervention (additionnal psychological assessment)OtherThe only intervention prompted by the research involves referring patients with an EPDS score of ≥10 and/or a positive response to item 10 of the scale ('has already thought about harming themselves') to a psychologist.
Receives: Other: psychological assessment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Effect of visitor restriction levels implemented in maternity wards on mothers' postnatal depressive symptoms

    The incidence of depressive symptoms in the mother using the Edinburgh Postnatal Depression Scale (EPDS)

    Measured: At discharge from hospitalization in the maternity ward, on average 48 hours

  2. Effect of visitor restriction levels implemented in maternity wards on early indicators of newborn health.

    Neonatal weight change between birth and discharge from the maternity ward, reflecting the newborn's early health status.

    Measured: Until discharge from hospitalization in the maternity ward, on average 48 hours.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jun 2026
  2. Study start19 Jun 2026
  3. Primary completionJun 2028 (estimated)
  4. Study completionJun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Model description
The VISIMAT prospective multicentre cohort study will be implemented in several maternity units across the Auvergne-Rhône-Alpes (AuRA) region. This is a non-randomised, low-risk, low-burden interventional study that compares the postpartum health status of mothers and newborns according to the level of restrictions on visits applied in their maternity unit. The only intervention resulting from the research consists of referring patients with an EPDS score ≥ 10 and/or a positive response to item 10 of this scale ('has already thought about harming themselves') to a psychologist.
Masking
None (open label)
Enrolment
8,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07653646
Sponsor's protocol ID
24-08
Acronym
VISIMAT
Status last verified
Oct 2026
First submitted
28 May 2026
Last updated
22 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing psychological assessment in people with Post Partum Women and Newborn Health, run by Centre Hospitalier Annecy Genevois at 2 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Marion Beucher, PhD (+33450637032 ext. +33, mbeucher@ch-annecygenevois.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Effect of visitor restriction levels implemented in maternity wards on mothers' postnatal depressive symptoms (time frame: At discharge from hospitalization in the maternity ward, on average 48 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in